Rheumatoid arthritis registries in Sweden.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical and Experimental Rheumatology

• Publication date

  2005-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 16273807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The British Society for Rheumatology Biologics Register

  2005cited by this paper
• Infliximab in active early rheumatoid arthritis

  2004cited by this paper
• Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

  2004cited by this paper
• Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious

  2003influential reference
• TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

  2003cited by this paper
• Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense

  2003cited by this paper
• [The National Database of the Regional Collaborative Rheumatic Centers as a tool for clinical epidemiology and quality assessment in rheumatology].

  2003cited by this paper
• Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry.

  2003cited by this paper
• Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study.

  2003cited by this paper
• [New drugs and treatment strategies for rheumatoid arthritis].

  2003cited by this paper
• CANDOO and CANOAR, CORRONA and more: advancing therapeutics through layered-in clinical data collection and feedback at the point of care.

  2003cited by this paper
• Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.

  2003influential reference
• Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

  2003cited by this paper
• The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing.

  2003cited by this paper
• Clinical responses to tumor necrosis factor α antagonists do not show a bimodal distribution: Data from the Stockholm Tumor Necrosis Factor α Followup Registry

  2003cited by this paper
• Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden

  2002cited by this paper
• The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.

  2002cited by this paper
• Limitations of randomized clinical trials in chronic diseases: explanations and recommendations.

  2002cited by this paper
• Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity.

  2001cited by this paper
• Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment.

  2001cited by this paper
• Arthritis, Rheumatism and Aging Medical Information System Post-Marketing Surveillance Program.

  2001cited by this paper
• Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

  2000cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

  1999influential reference
• [A pilot project to learn quality development: care of patients with recently diagnosed rheumatic arthritis].

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

  1999cited by this paper
• Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies.

  1997cited by this paper
• The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register.

  1994cited by this paper
• ARAMIS (the American Rheumatism Association Medical Information System). A prototypical national chronic-disease data bank.

  1986cited by this paper
• The chronic disease data bank: first principles to future directions.

  1984cited by this paper

• Role of rheumatoid arthritis registries worldwide: What have they taught us?

  2024cites this paper
• Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

  2024cites this paper
• Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration

  2023cites this paper
• Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records

  2022cites this paper
• One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment

  2022cites this paper
• Developing A Minimum Data Set for A Rheumatoid Arthritis Registry in Iran

  2022cites this paper
• North-Western register of patients with inflammatory bowel diseases: achievements and lessons learned

  2022cites this paper
• Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision

  2021cites this paper
• Value of learning healthcare systems in transforming clinical quality registries: is this the next frontier?

  2021cites this paper
• Registers as the basis for data collection and evidence building

  2021cites this paper
• Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry

  2019cites this paper
• Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

  2019cites this paper
• Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

  2018cites this paper
• Patient-reported outcome measurements in clinical routine of trauma, spine and craniomaxillofacial surgeons: between expectations and reality: a survey among 1212 surgeons

  2018cites this paper
• Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011

  2018cites this paper
• The use of routinely collected patient-reported outcome measures in rheumatoid arthritis.

  2018cites this paper
• Incidence rates of malignancy and precancerous lesions in Newfoundland and Labrador population with immune mediated inflammatory diseases: psoriatic arthritis and rheumathoid arthritis

  2018cites this paper
• Cohort Profile Cohort Profile : The AMORIS cohort

  2017cites this paper
• Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers.

  2017cites this paper
• Development and Methodology of a Registry of Regional Anaesthesia

  2017cites this paper
• Revue systématique des registres de polyarthrites rhumatoïdes sous biothérapie dans le monde et méta-analyse sur les données de tolérance

  2017cites this paper
• Registries in Spondyloarthritis: What have we Learned?

  2017cites this paper
• Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study.

  2017cites this paper
• Biologics registers in RA: methodological aspects, current role and future applications

  2017cites this paper
• Current Treatment Outcomes Among Patients with Rheumatoid Hand and Wrist Deformities

  2016cites this paper
• Primary and secondary patient data in contrast: the use of observational studies like RABBIT.

  2016cites this paper
• Off-label use of rituximab for systemic lupus erythematosus in Europe

  2016cites this paper
• Diffusion, implementation and consequences of new health technology The cases of biological drugs for rheumatoid arthritis and the Swedish national guidelines

  2015cites this paper
• Improving the Quality of Care of Patients With Rheumatic Disease Using Patient‐Centric Electronic Redesign Software

  2015cites this paper
• Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

  2015cites this paper
• Characteristics of Patients With Rheumatoid Arthritis in Turkey: Results From the Turkish League Against Rheumatism Rheumatoid Arthritis Registry

  2015cites this paper
• SveDem, the Swedish Dementia Registry – A Tool for Improving the Quality of Diagnostics, Treatment and Care of Dementia Patients in Clinical Practice

  2015cites this paper
• Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register‐Based Study of 4,010 Patients in Sweden

  2015cites this paper
• Anti-TNF therapy and malignancy in patients with rheumatoid arthritis : studies on cancer incidence, recurrence and survival

  2014cites this paper
• Factors influencing rheumatologists’ prescription of biological treatment in rheumatoid arthritis: an interview study

  2014cites this paper
• Comparison of characteristics of international and national databases for rheumatoid arthritis: a systematic literature review

  2014cites this paper
• Person-centred care in rheumatology nursing in patients undergoing biological therapy

  2013cites this paper
• The Crafoord Prize in Polyarthritis 2013: significant discoveries and remaining challenges.

  2013cites this paper
• Safety of long-term anti-TNF use, with respect to malignancy, in a national cohort of people with rheumatoid arthritis

  2013cites this paper
• Improving clinical outcomes in rheumatoid arthritis : a patient centred approach

  2013cites this paper
• Cross-country variation in medicines use; a pharmaceutical system perspective

  2013cites this paper
• Person-centred care in rheumatology nursing in patients undergoing biological therapy : An explorative and interventional study

  2013cites this paper
• The importance of rheumatology biologic registries in Latin America

  2013cites this paper
• Randomized controlled trial of a nurse-led rheumatology clinic for monitoring biological therapy

  2013cites this paper
• Biologic registries in rheumatology: lessons learned and expectations for the future.

  2012cites this paper
• Abstracts of the American College of Rheumatology & Association of Rheumatology Health Professionals, Annual Scientific Meeting. November 9-14, 2012. Washington, D.C., USA.

  2012cites this paper
• Medical registers in rheumatology: do we need a rheumatology register in Poland?

  2012cites this paper
• Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

  2011cites this paper
• GISEA:anItalianbiologicalagentsregistry inrheumatology Il registro Italiano del Gruppo GISEA

  2011cites this paper
• Quality and completeness of utilisation data on biological agents across European countries: tumour necrosis factor alpha inhibitors as a case study

  2011cites this paper
• Reuma.pt - the rheumatic diseases portuguese register.

  2011cites this paper
• Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN).

  2011cites this paper
• BiobadaBrasil: Brazilian biologic registry.

  2011cites this paper
• Outcomes research in rheumatoid arthritis.

  2011cites this paper
• GISEA: an Italian biological agents registry in rheumatology.

  2011cites this paper
• Registro brasileiro de biológicos: processo de implementação e resultados preliminares do BiobadaBrasil

  2011cites this paper
• Progress on the Development of a Benefit / Risk Framework for Evaluating Medicines

  2010cites this paper
• [Early rheumatoid arthritis: concepts].

  2010cites this paper
• Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP

  2010cites this paper
• Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence

  2010cites this paper
• Methods to analyze real-world databases and registries.

  2009cites this paper
• CHAPTER 12B – Registries in Rheumatic Disease Epidemiology

  2009cites this paper
• CHAPTER 12A – European Biologics Registers

  2009cites this paper
• Health-related quality of life in Swedish men and women with early rheumatoid arthritis.

  2009cites this paper
• EXPLORING A NATIONAL PRACTICE- BASED REGISTER FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS

  2008cites this paper
• Socioeconomic and occupational risk factors for rheumatoid arthritis: a nationwide study based on hospitalizations in Sweden.

  2008cites this paper
• The role of drug and disease registries in rheumatic disease epidemiology

  2008cites this paper
• European biologicals registers: methodology, selected results and perspectives

  2008cites this paper
• The effectiveness and medication costs of three anti-tumour necrosis factor α agents in the treatment of rheumatoid arthritis from prospective clinical practice data

  2007cites this paper
• Scandinavian registers in normal and arthritic populations.

  2007cites this paper
• All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

  2007cites this paper
• Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database

  2007cites this paper
• Joint Destruction in Rheumatoid Arthritis: Experimental, Clinical and Epidemiological Studies

  2007cites this paper
• Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials.

  2006cites this paper
• Disease activity, function and costs in early rheumatoid arthritis

  2006cites this paper
• SveDem, the Swedish Dementia Registry - A Tool for Improving the Quality of Diagnostics, Treatment and Care of Dementia Patients in Clinical Practice.

  year unknowncites this paper
• SveDem, the Swedish Dementia Registry - A Tool for Improving the Quality of Diagnostics, Treatment and Care of Dementia Patients in Clinical Practice.

  year unknowncites this paper
• SveDem, the Swedish Dementia Registry - A Tool for Improving the Quality of Diagnostics, Treatment and Care of Dementia Patients in Clinical Practice.

  year unknowncites this paper
• SveDem, the Swedish Dementia Registry - A Tool for Improving the Quality of Diagnostics, Treatment and Care of Dementia Patients in Clinical Practice.

  year unknowncites this paper